Abbott Labs Beats Expectations with Strong Q1 Results Despite Covid-19 Declines.
TL;DR Summary
Abbott Laboratories beat expectations in Q1 2021, driven by strong sales growth in its medical devices segment, particularly in heart valve, heart failure, and neuromodulation products. Organic sales growth remained strong, with sales growing 10% organically. Abbott's stock surged 7.8% in response to the earnings release, reaching its highest point since late January. The company expects earnings of $4.30-$4.50 per share and organic sales growth in a high-single-digit range, excluding its Covid-19 tests.
- ABT Stock: Abbott Shakes Off Covid Declines To Beat Expectations | Investor's Business Daily Investor's Business Daily
- Abbott Labs shares pop as revenue, earnings defy steep drop in Covid test sales CNBC
- Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business Press Releases
- Why Abbott Laboratories Shares Are Trading Higher Today? Yahoo Finance
- Abbott Labs Sales, Earnings Defy Slowdown in Covid-19 Tests. Stock Rises. Barron's
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
87%
555 → 73 words
Want the full story? Read the original article
Read on Investor's Business Daily